Navigation Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Navigation Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$346K	Hold	696	–	–	0.07%	104
2026 Q1	$311K	Buy	+696	New	+$325K	0.07%	100

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Navigation Group's VRTX Position: Q2 2026 in Review

Navigation Group held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 696 shares worth $346K. The position accounts for 0.07% of the portfolio, ranked #104.

Navigation Group first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,743 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Navigation Group held 696 shares of Vertex Pharmaceuticals worth $346K as of Q2 2026.
Navigation Group left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.07% of Navigation Group's portfolio in Q2 2026, its #104 holding.
Navigation Group first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
1,743 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Navigation Group's 13F filing for Q2 2026, filed 29 Jul 2026.